Cure My Disease

Don't miss your cure!

 Log in / Sign up

New light probe offers hope for menopause vaginal pain

NCT ID NCT05058313

Symptom relief Sponsor: Centre Hospitalier Universitaire de Nīmes Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new vaginal probe that uses special lights to treat vaginal atrophy in 25 postmenopausal women who had not been helped by other treatments. The probe aims to reduce pain and dryness by stimulating natural tissue repair. The main goal was to check safety and see if it eases symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

25 people

The number who actually took part.

Started

Mar 2022

Finished

May 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient with pelvic discomfort/pain (pain, dryness, irritation, etc.) due to vaginal atrophy that has failed all non-invasive therapies for over 3 months. * Postmenopausal patient recruited during a consultation in the Gynecology department of the University Hospital of Nîmes or at the KARIS Medical Center in Perpignan and having undergone a complete clinical examination allowing any physical and / or psychological cause to be eliminated. * Patient who has given her free and informed consent. * Patient affiliated or beneficiary of a health insurance plan. Exclusion Criteria: * Patient not available for the 6-week follow-up. * Patient presenting with pelvic pain of physical and / or psychological origin. * Patients undergoing initial treatment for cancer and/or who have completed their treatments within the last year * Patient with immunosuppression. * Allergy to the material of the probe protection used (latex for example). * Pregnancy. * Implantable device active in the heart such as a defibrillator or a pacemaker, neuromodulation stimulator, electrodes implanted for the treatment of Parkinson's disease. * Epilepsy, photophobia, recent intake of photosensitizing drugs or cosmetics (in the last 6 months), history of porphyria. * Patient participating in category 1 interventional study. * Patient in an exclusion period determined by another study. * Patient under legal protection, under guardianship or under curatorship. * Patient for whom it is impossible to give informed information.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrophic vaginitis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

postmenopausal atrophic vaginitis Urinary Incontinence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrophic vaginitis Menopause Urinary incontinence

Contacts and locations

Locations

  • CHU Nîmes

    Nîmes, France

  • Centre Hospitalier de Valenciennes

    Valenciennes, 59322, France

  • Centre Médical KARIS

    Perpignan, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.